SEC Filing Analysis: Nurix Therapeutics, Inc. (NRIX)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Chief Financial Officer of Nurix Therapeutics conducted a small, pre-planned sale of common stock valued at approximately $79k.
• Market Impact: The transaction is immaterial relative to the company's market capitalization and is not expected to have a notable market impact.

Company Information

Field	Value
Company	Nurix Therapeutics, Inc.
Ticker Symbol	NRIX
CIK	0001549595
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	van Houte Hans
CIK	0001817217
Title/Position	Chief Financial Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-03
Transaction Code	S (Sale)
Security Type	Common Stock
Shares Involved	6,284
Price Per Share	$12.5607
Total Value	$78,924.96
Shares Owned After	37,592
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$78,924.96
% of Market Cap	0.006%
Shares Transacted	6,284
% of Shares Outstanding	0.008%
Post-Transaction Ownership	37,592 shares (0.049% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a company with a $1.31 billion market capitalization, this transaction of less than $80k is considered routine and financially insignificant.
• Ownership Concentration: The sale represents approximately 14.3% of the insider's prior holdings. While a notable portion for the individual, the CFO's total ownership remains very small at less than 0.05% of total shares outstanding.
• Transaction Significance: The transaction's value is far below 0.1% of the market cap and the shares involved are far below 0.1% of shares outstanding, confirming its low significance.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sale is minor in value and was executed under a pre-arranged Rule 10b5-1 trading plan. Such plans are established in advance to avoid trading on non-public information, making the transaction a poor indicator of the insider's current sentiment.

Volume & Sentiment

• Expected Volume Impact: Negligible. The transaction size is too small to impact trading volume.
• Sentiment Indicator: Neutral. Pre-planned sales by executives for personal financial management are common and do not typically signal a change in outlook for the company.

Additional Context

Special Circumstances

• The filing explicitly states this transaction was made pursuant to a Rule 10b5-1 trading plan, which diminishes its significance as a market signal.